Achieving Equity in Precision Medicine: Early Detection of Cancer
Most medical professionals have insufficient knowledge about the role that precision medicine has in clinical practice. Genetic alterations affect all types of cancer and often affect cardiovascular, autoimmune, and neurological diseases. Laboratory tools used in precision medicine are highly sophisticated and include genomics, proteomics, and other high-dimensional assays. The series will provide regular updates on these tools, the ways the tools could improve patient care, and the ethical and legal issues surrounding genetic testing. The series will also examine how testing for genetically influenced diseases can affect personalized management of individuals and their families.
Physicians, residents, fellows, medical students, nurses, and other health professionals.
At the conclusion of the session, the participants should be able to:
- Discuss the biological and social determinants of cancer disparities.
- Evaluate the potential pitfalls of novel technologies to generate cancer inequities.
- Explore the need for data diversity to understand and eliminate cancer disparities.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Thank you for reviewing this Baylor College of Medicine on-demand activity. In order to complete the evaluation and claim credit for your participation, please select the appropriate payment option above. After payment has been completed, you will receive an email confirmation and receipt.
For any questions, contact email@example.com.